New hope for tough blood cancers: early trial tests promising pill
NCT ID NCT02029443
Summary
This study tested a new oral medication called acalabrutinib for adults with chronic lymphocytic leukemia (CLL) and related cancers that have come back or stopped responding to other treatments. The main goals were to find a safe dose and see if the drug could shrink the cancer. Researchers enrolled 306 participants to see how their bodies handled the drug and how well it worked.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Boston, Massachusetts, 2215, United States
-
Research Site
New Hyde Park, New York, 11042, United States
-
Research Site
New York, New York, 10021, United States
-
Research Site
Columbus, Ohio, 43210, United States
-
Research Site
Fort Worth, Texas, 76104, United States
-
Research Site
Salt Lake City, Utah, 84112, United States
-
Research Site
Seattle, Washington, 98122, United States
-
Research Site
Tacoma, Washington, 98405, United States
-
Research Site
Milan, 20132, Italy
-
Research Site
Leeds, LS9 7TF, United Kingdom
-
Research Site
London, SE5 9RS, United Kingdom
-
Research Site
Oxford, OX3 7LE, United Kingdom
Conditions
Explore the condition pages connected to this study.